MILESTONE SCIENTIFIC INC. Financials Milestone Scientific Inc.
Equities
MLSS
US59935P2092
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.56 USD | -1.75% |
|
+1.63% | -18.83% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 67.95 | 135 | 139.8 | 33.5 | 52.28 | 42.9 | - |
| Enterprise Value (EV) 1 | 67.95 | 135 | 139.8 | 33.5 | 52.28 | 42.9 | 42.9 |
| P/E ratio | -8.69 x | -17.7 x | -20.6 x | -4 x | -6.9 x | -11.2 x | -14 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.11 x | 24.8 x | 13.6 x | 3.8 x | 5.32 x | 3.92 x | 3.39 x |
| EV / Revenue | 8.11 x | 24.8 x | 13.6 x | 3.8 x | 5.32 x | 3.92 x | 3.39 x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 48,885 | 63,693 | 67,846 | 69,795 | 75,780 | 76,602 | - |
| Reference price 2 | 1.390 | 2.120 | 2.060 | 0.4800 | 0.6899 | 0.5600 | 0.5600 |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/30/23 | 3/29/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.374 | 5.437 | 10.3 | 8.806 | 9.827 | 10.94 | 12.64 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -3.999 | -7.453 | -7.379 | -8.827 | -7.106 | -4.163 | -3.301 |
| Operating Margin | -47.75% | -137.08% | -71.6% | -100.24% | -72.31% | -38.07% | -26.11% |
| Earnings before Tax (EBT) 1 | -7.562 | -7.471 | -7.119 | -8.773 | -6.981 | -4.147 | -3.28 |
| Net income 1 | -7.524 | -7.337 | -6.818 | -8.706 | -6.929 | -4.158 | -3.293 |
| Net margin | -89.85% | -134.94% | -66.17% | -98.87% | -70.51% | -38.02% | -26.05% |
| EPS 2 | -0.1600 | -0.1200 | -0.1000 | -0.1200 | -0.1000 | -0.0500 | -0.0400 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/30/23 | 3/29/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.108 | 2.846 | 2.701 | 1.648 | 2.216 | 2.241 | 2.598 | 2.91 | 2.059 | 2.261 | 2.416 | 2.623 | 2.824 | 3.072 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.981 | -1.541 | -1.914 | -2.885 | -2.014 | -2.015 | -1.343 | -2.278 | -1.507 | -1.98 | -1.499 | -1.011 | -0.868 | -0.784 |
| Operating Margin | -93.96% | -54.13% | -70.88% | -175.01% | -90.87% | -89.9% | -51.69% | -78.27% | -73.17% | -87.57% | -62.04% | -38.54% | -30.74% | -25.52% |
| Earnings before Tax (EBT) 1 | -1.986 | -1.545 | -1.919 | -2.881 | -1.985 | -1.987 | -1.319 | -2.229 | -1.476 | -1.991 | -1.495 | -1.007 | -0.864 | -0.78 |
| Net income 1 | -2.043 | -1.122 | -1.902 | -2.858 | -1.972 | -1.974 | -1.308 | -2.216 | -1.466 | -1.939 | -1.497 | -1.01 | -0.867 | -0.783 |
| Net margin | -96.92% | -39.42% | -70.41% | -173.41% | -88.99% | -88.09% | -50.34% | -76.16% | -71.2% | -85.77% | -61.96% | -38.51% | -30.7% | -25.49% |
| EPS 2 | -0.0300 | -0.0200 | -0.0300 | -0.0400 | -0.0300 | -0.0200 | -0.0200 | -0.0300 | -0.0200 | -0.0300 | -0.0200 | -0.0100 | -0.0100 | -0.0100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 3/31/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/30/23 | 5/10/23 | 8/14/23 | 11/14/23 | 3/29/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/30/23 | 3/29/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.56
USD
Average target price
3
USD
Spread / Average Target
+435.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.83% | 42.9M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- MLSS Stock
- Financials Milestone Scientific Inc.
